Metly, an intelligence layer for pharmaceutical business development teams, secured €520,000 in an oversubscribed pre-seed funding round. Encomenda led the investment, with participation from Ona Capital, Dozen Investments, and strategic angel investors. This Metly pre-seed funding will accelerate the discovery and execution of pharma licensing and manufacturing partnerships.
The platform leverages AI agents to streamline a traditionally manual process. It identifies new licensing and manufacturing opportunities, assesses strategic fit, and connects partners directly. This significantly shortens timelines for bringing new products to market.
Accelerating Pharma Business Development with AI
Metly's AI continuously scans public and proprietary data. It surfaces high-fit opportunities based on specific company needs. Teams then discover and contact relevant partners through integrated outreach tools, offering a more efficient alternative to traditional methods.
The platform currently hosts over 35,000 licensed products from 550 global licensors. Expansion into the US and China is underway. This Metly pre-seed funding supports scaling its artificial intelligence technology and growing technical and commercial teams. Other companies like BenevolentAI and Exscientia also apply AI within the broader healthcare technology sector. The investment further fuels Metly's international growth, marking a significant step in its startup funding journey.